Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chlamydial pelvic inflammatory disease

J Paavonen1, M Lehtinen

  • 1Department of Obstetrics and Gynecology, University of Helsinki, Finland. jpaavone@cc.Helsinki.Fi

Human Reproduction Update
|November 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial.

BMJ open·2022
Same author

ESTIMATION OF HP(3) AMONG STAFF MEMBERS IN TWO NUCLEAR MEDICINE UNITS IN FINLAND.

Radiation protection dosimetry·2020
Same author

Erratum for Hokynar et al., "Molecular Evidence of <i>Chlamydia</i>-Like Organisms in the Feces of <i>Myotis daubentonii</i> Bats".

Applied and environmental microbiology·2019
Same author

Superselective endovascular tissue access using trans-vessel wall technique: feasibility study for treatment applications in heart, pancreas and kidney in swine.

Journal of internal medicine·2018
Same author

Serum antibody response to Chlamydia trachomatis TroA and HtrA in women with tubal factor infertility.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2018
Same author

Molecular Evidence of Chlamydia-Like Organisms in the Feces of Myotis daubentonii Bats.

Applied and environmental microbiology·2016

Screening for chlamydia infections is crucial for preventing pelvic inflammatory disease (PID). Early detection and treatment of chlamydia in sexually active individuals can significantly reduce PID incidence and its severe complications.

Area of Science:

  • Reproductive Health
  • Infectious Diseases
  • Public Health

Background:

  • Pelvic inflammatory disease (PID) is a significant complication of lower genital tract infections in women, leading to substantial medical, social, and economic burdens.
  • PID most commonly arises from ascending infections of Chlamydia trachomatis or Neisseria gonorrhoeae from the cervix.
  • While gonococcal infections have declined, chlamydial infections remain prevalent, underscoring their importance in PID pathogenesis.

Purpose of the Study:

  • To highlight the critical role of cervical chlamydial infection in the development of PID.
  • To emphasize the effectiveness of screening for chlamydial infections in the secondary prevention of PID.
  • To discuss advancements in diagnostic and therapeutic strategies for chlamydia control and PID prevention.

Main Methods:

Related Experiment Videos

  • Review of recent epidemiological data on chlamydial and gonococcal infections.
  • Analysis of evidence supporting the impact of screening on PID incidence.
  • Evaluation of technological advancements in diagnostics and treatment for chlamydia control.

Main Results:

  • Chlamydial infections are a primary driver of PID, with high incidence rates in many countries.
  • Universal or targeted screening for cervical chlamydial infection significantly reduces PID rates.
  • New technologies like gene amplification tests and single-dose antimicrobial therapy enhance chlamydia control programs.

Conclusions:

  • Screening for chlamydia is the cornerstone of secondary prevention for PID.
  • Integrating chlamydia screening into routine healthcare for young, sexually active individuals is essential.
  • Developing improved interventions to prevent long-term sequelae of PID remains a critical public health challenge.